Introduction {#s1}
============

Infertility is a common clinical problem affecting 15% of couples; ovulatory disorders account for 25% of this total ([@bib30]). The hypothalamic-pituitary-gonadal axis controls reproduction and malfunction of this axis can cause ovulatory dysfunction and/or other disturbances of the reproductive cycle ([@bib21]; [@bib40]). Gonadotropin-releasing hormone (GnRH) neurons form the final common pathway for central neural regulation of reproduction. GnRH stimulates the pituitary to secrete follicle-stimulating hormone and luteinizing hormone (LH), which regulate gonadal steroid and gamete production. Estradiol, via estrogen receptor alpha (ERα), plays crucial roles in both homeostatic negative feedback and positive feedback action on GnRH/LH release in females ([@bib12]; [@bib34]; [@bib29]; [@bib24]; [@bib56]; [@bib6]; [@bib16]; [@bib4]). Low estradiol levels suppress pulsatile GnRH/LH release, whereas sustained elevations in estradiol during the late follicular phase of the cycle cause a switch of estradiol feedback action from negative to positive, inducing prolonged GnRH/LH surges, which ultimately triggers ovulation ([@bib7]). As GnRH neurons typically do not express detectable ERα ([@bib23]), estradiol feedback is likely transmitted to GnRH neurons by ERα-expressing afferents.

Kisspeptin neurons in the arcuate and anteroventral periventricular (AVPV) regions are estradiolsensitive GnRH afferents that are postulated to mediate estradiol negative and positive feedback, respectively ([@bib36]; [@bib28]). Kisspeptin potently stimulates GnRH neurons and *Kiss1* mRNA is differentially regulated in these nuclei by estradiol ([@bib19]; [@bib32]; [@bib47]; [@bib38]; [@bib28]; [@bib26]; [@bib57]). ERα in kisspeptin cells is critical for estradiol negative and positive feedback, as kisspeptin-specific ERα knockout (KERKO) mice exhibit higher frequency LH pulses and fail to exhibit estradiol-induced LH surges ([@bib31]; [@bib14]; [@bib18]; [@bib55]). Although informative, the KERKO model has several caveats that limit interpretation. First, ERα is deleted as soon as *Kiss1* is expressed, before birth in arcuate kisspeptin neurons (also called KNDy neurons for coexpression of kisspeptin, neurokinin B and dynorphin) and before puberty in AVPV kisspeptin neurons ([@bib46]; [@bib25]). This may cause developmental changes in these cells and/or their networks. Second, ERα is deleted from all kisspeptin cells, thus making it impossible to assess independently the role of AVPV and arcuate kisspeptin neurons.

Combining CRISPR-Cas9 with targeted viral vector injection allows deletion of ERα in a nucleus-specific and temporally-controlled manner to address the above caveats ([@bib49]). We designed Cre-dependent AAV vectors that carry single guide RNAs (sgRNAs) that target *Esr1* (encoding ERα) or *lacZ* and delivered these vectors to the AVPV or arcuate of adult female mice that express Cas9 in kisspeptin cells. We then compared the reproductive phenotypes as well as kisspeptin neuronal physiology in AAV-*Esr1* vs AAV-*lacZ* targeted mice and KERKO mice.

Results {#s2}
=======

AVPV kisspeptin neurons from KERKO mice exhibit decreased firing rate and excitability {#s2-1}
--------------------------------------------------------------------------------------

We first used extracellular recordings to monitor the spontaneous firing rate of YFP-identified AVPV kisspeptin neurons in coronal brain slices from ovary-intact control and KERKO mice. As the persistent cornified vaginal cytology of KERKO mice is similar to that observed during estrus ([@bib18]), we used mice in the estrous stage of the reproductive cycle as controls. The firing frequency of AVPV kisspeptin neurons was lower in ovary-intact KERKO mice compared to controls ([Figure 1a,b](#fig1){ref-type="fig"}, two-way ANOVA/Holm-Sidak, p=0.0001). To test if the firing rate of AVPV kisspeptin neurons in KERKO mice responds to circulating estradiol, we repeated this study in ovariectomized (OVX) mice and OVX mice with an estradiol implant producing constant physiologic levels (OVX + E) ([@bib5]). OVX reduced and estradiol treatment increased firing rate in cells from control, but not KERKO, mice ([Figure 1a,b](#fig1){ref-type="fig"} two-way ANOVA/Holm-Sidak, control intact vs OVX p=0.009, intact vs OVX + E, p=0.02, OVX vs OVX + E, p\<0.0001). As a result of this difference, the firing frequency is higher in cells from OVX + E control than OVX + E KERKO mice (p\<0.0001). Statistical test parameters for all figures are in [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}.

![AVPV kisspeptin neurons from KERKO mice are less excitable compared to those from control mice and are not regulated by estradiol.\
(**a**) Representative extracellular recordings for cells from control and KERKO mice from ovary-intact, OVX and OVX +E groups. (**b**) Individual values and mean ± SEM firing frequency of cells from control (white circles) and KERKO groups (black circles). (**c**) representative depolarizing (magenta,+20 pA, 500 ms) and hyperpolarizing (black, −20 pA, 500 ms) firing signatures for cells from control and KERKO mice in ovary-intact (left), OVX (middle) and OVX +E (right) groups; black arrows indicate rebound bursts and red arrows indicate depolarization-induced bursts (DIB). Initial membrane potential was 70 ± 2 mV. (**d**) and (**e**) percent of cells exhibiting DIB (**d**) or rebound (**e**) bursts; cells per group is shown within the bar. (**f**) Input-output curves for cells from control and KERKO mice; ovary-intact (left), OVX (middle) and OVX +E (right). \*p\<0.05.](elife-43999-fig1){#fig1}
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###### Statistical parameters for two-way ANOVA.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                     Figure                                                       Factor 1                 Factor 2               Interaction
  ----------------------------- ------------------------------------------------------------ ------------------------ ---------------------- ----------------------
  Firing frequency              [Figure 1b](#fig1){ref-type="fig"}                           steroid\                 genotype\              \
                                                                                             F (2, 57)=14.7 ^\*^      F (1, 57)=40.1 ^\*^    F (2, 57)=6.2 ^\*^

  Input-output curve            [Figure 1f](#fig1){ref-type="fig"} intact\                   current\                 genotype\              \
                                OVX\                                                         F (4, 80)=242.7 ^\*^\    F (1, 20)=8.2 ^\*^\    F (4, 80)=0.6\
                                OVX + E                                                      F (4, 72)=138.6 ^\*^\    F (1, 18)=0.8\         F (4, 72)=0.7\
                                                                                             F (4, 84)=182.2 ^\*^     F (1, 21)=6.6 ^\*^     F (4, 84)=1.5

  I~T~ current density          [Figure 2b](#fig2){ref-type="fig"}                           voltage\                 genotype\              \
                                                                                             F (8, 104)=39.74 ^\*^    F (1, 13)=11.1 ^\*^    F (8, 104)=9.4 ^\*^

  I~T~ normalized conductance   [Figure 2c](#fig2){ref-type="fig"} activation inactivation   voltage\                 genotype\              \
                                                                                             F (8, 104)=494.7 ^\*^\   F (1, 13)=3.2\         F (8, 104)=1.5\
                                                                                             F (8, 104)=195.8 ^\*^    F (1, 13)=4.5 ^\*^     F (8, 104)=3.1 ^\*^

  LH                            [Figure 3f](#fig3){ref-type="fig"}\                          AAV type\                time\                  \
                                [Figure 3g](#fig3){ref-type="fig"}                           F (1, 12)=29.8 ^\*^\     F (2, 24)=2.1\         F (2, 24)=1.8\
                                                                                             F (1, 13)=0.3            F (1, 13)=35.8 ^\*^    F (1, 13)=19.5 ^\*^

  Input-output curve            [Figure 4d](#fig4){ref-type="fig"}\                          current\                 AAV type\              \
                                IF post hoc\                                                 F (4, 136)=165.5 ^\*^\   F (2, 34)=7.2 ^\*^\    F (8, 136)=0.7\
                                PCR post hoc\                                                F (4, 68)=123 ^\*^\      F (1, 17)=12.5 ^\*^\   F (4, 68)=4.3^\*^\
                                AAV-*Esr1* vs KERKO                                          F (4, 100)=154.7 ^\*^    F (1, 25)=2.1          F (4, 100)=7.2

  Days proestrus/week           [Figure 5d](#fig5){ref-type="fig"}                           time\                    AAV type\              \
                                                                                             F (1, 12)=13.6 ^\*^      F (2, 12)=5.8 ^\*^     F (2, 12)=10.0 ^\*^

  LH                            [Figure 5g](#fig5){ref-type="fig"} kisspeptin\               injection\               AAV type\              \
                                GnRH                                                         F (1, 12)=34.8 ^\*^\     F (1, 12)=4.7 \#\      F (1, 12)=17.1 ^\*^\
                                                                                             F (1, 12)=20.0 ^\*^      F (1, 12)=7.0 ^\*^     F (1, 12)=7.5 ^\*^

                                                                                             steroids                 genotype               interaction

  Input resistance              [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}   F (2, 59)=2.6            F (1, 59)=13.2 ^\*^    F (2, 59)=2.0

  Cell capacitance              [Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}   F (2, 59)=5.2            F (1, 59)=0.1 ^\*^     F (2, 59)=0.4

  Normalized uterine mass       [Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}   F (2, 30)=19.9 ^\*^      F (1, 30)=80.0 ^\*^    F (2, 30)=2.4
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

^\*^p\<0.05, \# p=0.05.
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###### Statistical parameters for two group comparisons.

For normally distributed data, two-tailed unpaired Student's t-test; for non-normally distributed data, two-tailed Mann-Whitney U test.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                        Figure                                                       T or U, df
  ---------------------------------------------------------------- ------------------------------------------------------------ ---------------------
  V~1/2~ activation slope\                                         in the text, control vs KERKO\                               t = 1.7, 13\
  V~1/2~ inactivation slope inactivation                           I~T~ kinetics                                                t = 0.01, 13\
                                                                                                                                t = 2.5, 13\
                                                                                                                                t = 1.6, 13

  rate of rise IF rate of rise PCR\                                [Figure 4h](#fig4){ref-type="fig"}\                          t = 2.5, 27\
  FWHM IF\                                                         [Figure 4i](#fig4){ref-type="fig"}\                          t = 2.7, 17\
  FWHM PCR\                                                        [Figure 4j](#fig4){ref-type="fig"}                           U = 62 t = 3.1, 17\
  AHP amplitude IF\                                                                                                             t = 4.4, 27\
  AHP amplitude PCR                                                                                                             t = 2.7, 27

  LH pulses/h                                                      [Figure 5e](#fig5){ref-type="fig"}                           t = 1.7, 12

  Mean LH                                                          [Figure 5f](#fig5){ref-type="fig"}                           t = 0.05, 12

  Firing rate                                                      [Figure 6b](#fig6){ref-type="fig"}                           U = 45.5

  EPSC frequency                                                   [Figure 6e](#fig6){ref-type="fig"}                           t = 4.0, 20

  EPSC amplitude                                                   [Figure 6e](#fig6){ref-type="fig"}                           t = 2.7, 20

  Input resistance lacZ vs Esr1 IF, lacZ vs Esr1 PCR,\             [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}   t = 0.7, 27\
  KERKO vs Esr1                                                                                                                 t = 1.0, 17\
                                                                                                                                t = 1.8, 35

  Cell capacitance lacZ vs Esr1 IF, lacZ vs Esr1 PCR,\             [Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}   t = 0.4, 27\
  KERKO vs Esr1                                                                                                                 t = 0.3, 17\
                                                                                                                                t = 0.3, 35

  Normalized uterine mass lacZ vs Esr1 AVPV lacZ vs Esr1 arcuate   [Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}   t = 0.5, 14\
                                                                                                                                t = 2.9, 8
  ---------------------------------------------------------------------------------------------------------------------------------------------------

^\*^p\<0.05, \# p=0.05.

We next recorded the whole-cell firing signatures of neurons in these six groups in response to current injection. AVPV kisspeptin neurons in control mice mice exhibit a greater number of depolarization-induced bursts (DIB) and rebound bursts when estradiol is elevated, confirming previous observations ([@bib54]) ([Figure 1c,d,e](#fig1){ref-type="fig"}, Chi-square, DIB, p=0.02; rebound, p=0.02; Fisher's exact *post hoc* test, DIB, OVX vs OVX +E, p=0.008, rebound OVX vs OVX +E p=0.03, for other paired comparisons, p\>0.2). In KERKO mice, these two types of bursts were rare (\<25% of cells) in all steroid conditions tested and were not regulated by estradiol ([Figure 1c,d,e](#fig1){ref-type="fig"}, Chi-square, DIB, p=0.4, rebound, p=0.3). We also compared the action potential output of these cells in response to current injection (0--50 pA, 10 pA increments, 500 ms). Cells from ovary-intact KERKO mice generated fewer action potentials compared to controls. Action potential generation as a function of current injection was similar in cells from OVX control and OVX KERKO mice but was increased by estradiol only in control mice ([Figure 1f](#fig1){ref-type="fig"}, two-way repeated-measures ANOVA/Holm-Sidak, intact, 20 pA, p=0.03, 30 pA, p=0.06; OVX +E, 20 pA to 50 pA, p≤0.04). Reduced action potential firing of AVPV kisspeptin neurons from KERKO mice may be attributable at least in part to decreased input resistance compared to controls ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, two-way ANOVA/Holm-Sidak control vs KERKO, intact, p=0.006, OVX, p=0.7, OVX +E p=0.02).

As both depolarization-induced bursts and rebound bursts are sensitive to NiCl (100 µM) ([@bib27]) at levels that fairly specifically block T-type calcium channels, we measured T-type (I~T~) current density and voltage dependence. I~T~ current density was decreased in AVPV kisspeptin cells from gonad-intact KERKO mice compared to controls ([Figure 2a,b](#fig2){ref-type="fig"}, two-way repeated-measures ANOVA/Holm-Sidak, −50 mV, p=0.003; −40 mV, p=0.002; −30 mV, p=0.003). The voltage dependence of activation was not different between groups, but the voltage dependence of inactivation was depolarized in cells from KERKO mice ([Figure 2c](#fig2){ref-type="fig"}, control vs KERKO, two-tailed unpaired Student's *t*-test, V~1/2~ activation −52.2 ± 1.6 vs −48.6 ± 1.4 mV, p\>0.1; slope 5.5 ± 0.6 vs 5.5 ± 0.7, p\>0.1; V~1/2~ inactivation −74.8 ± 4.1 vs −61.9 ± 3.1 mV, p=0.03; slope −3.1 ± 0.5 vs −4.2 ± 0.3, p=0.1).

![T-type calcium currents are reduced in AVPV kisspeptin neurons from KERKO compared to control mice.\
(**a**) Voltage protocol (bottom right) and representative I~T~ in control (left) and KERKO groups (right). (**b**) Mean ± SEM I~T~ current density in control (white symbols) and KERKO groups (black symbols). (**c**) Voltage dependence of I~T~ conductance activation and inactivation in cells from control and KERKO mice. \*p\<0.05.](elife-43999-fig2){#fig2}

Design and validation of sgRNAs that target *Esr1* {#s2-2}
--------------------------------------------------

A caveat of studying the role of ERα in AVPV kisspeptin neurons using KERKO mice is that the deletion of ERα (encoded by *Esr1*) using cre recombinase under the control of the kisspeptin promoter is neither time- nor location-specific. We utilized the CRIPSR-Cas9 approach to achieve temporal and spatial control of *Esr1* gene knockdown. Two sgRNAs were designed that target exon1 of *Esr1* based on software prediction ([@bib43]); sites predicted by FengZhang's guide design software (<http://crispr.mit.edu>) as possible off-target regions for binding of these guides are listed in [Table 3](#table3){ref-type="table"}. The efficiency of each guide was tested in vitro in C2C12 mouse myoblast cells ([@bib33]). The sgRNAs that target *Esr1* and a sgRNA that targets *lacZ* as a control were subcloned into the lentiCRISPRv2 plasmid ([@bib45]), from which Cas9 and the sgRNA are expressed after transfection of C2C12 cells. Puromycin was used to select construct-expressing cells. After a \~ 4-week selection period, DNA was harvested and the *Esr1* region sequenced. Cells expressing either of the sgRNAs targeting *Esr1,* but not *lacZ*, exhibited a peak-on-peak sequencing pattern, indicating disruption of the gene ([Figure 3a](#fig3){ref-type="fig"}). As these in vitro experiments suggested these sgRNAs were able to mutate *Esr1*, we designed Cre-dependent AAV vectors to express each sgRNA and mCherry (to indicate infected cells) under control of the U6 promoter ([Figure 3b](#fig3){ref-type="fig"}). The AAV vector was bilaterally stereotaxically injected into the AVPV region of adult female mice that express Cas9 and GFP under control of the kisspeptin promoter (*Kiss1*-Cre; *Cas9 loxp*-stop-*Gfp*, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}); these groups are referred to as AVPV-AAV-*Esr1* or AVPV-AAV-*lacZ*. Only one guide was injected per animal to allow comparison of phenotypes when different areas of *Esr1* were targeted. The ERα knockdown efficiency of the two sgRNAs target *Esr1* was comparable. The infection rate for AVPV-AAV-*Esr1* was 81 ± 4% ([Figure 3d](#fig3){ref-type="fig"}, *Esr1*-guide 1 \[g1\] 82 ± 2%, n = 3; *Esr1*-guide 2 \[g2\] 81 ± 8%, n = 3) and only 28 ± 1% of AVPV kisspeptin cells expressed ERα post infection ([Figure 3d](#fig3){ref-type="fig"}, n = 3, *Esr1*-guide1 27 ± 0.4%; n = 3, *Esr1*-guide2 28 ± 2%). In mice that received AVPV-AAV-*lacZ* (n = 3), the infection rate was comparable at 82 ± 2%, but there was no disruption of ERα; 72 ± 2% of AVPV kisspeptin neurons expressed ERα, which is similar to control mice ([@bib26]). Of note, the ERα antibody used recognizes the C-terminus, suggesting a lack of rare splice variants that were generated at low levels in initial ERKO mice ([@bib9]).

![In vitro and in vivo validation of AVPV-AAV-*Esr1* guides.\
(**a**) Sequencing from C2C12 cells transiently transfected with lentiCRISPR v2 with sgRNAs targeting *Esr1* (guide 1 \[g1\] top, guide 2 \[g2\] middle) or lacZ. N in yellow highlight indicates peak on peak mutations. (**b**) and (**c**) Schematic representation of (**b**) the Cre-inducible AAV vector delivering sgRNAs and (**c**)* Kiss1*-cre *Cas9-loxp Stop-Gfp* mice. (**d**) AVPV-AAV-*lacZ*, -*Esr1* g1 or g2 were bilaterally delivered to the AVPV region (see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Brain sections were processed to detect GFP (green), mCherry (red) and ERα (black), dual GFP/mCherry detection indicates infection of kisspeptin neuron (white arrows, left panel of each pair). AVPV-AAV-*Esr1* infected AVPV kisspeptin neurons exhibit decreased ERα expression compared to AVPV-AAV-*lacZ* infected cells (right panel of each pair, white arrows indicate ERα-negative, magenta arrows indicate ERα-positive infected cells). (**e**) Representative reproductive cycles of mice that received AAV-*lacZ, g1 or g2*; E, estrus; D, diestrus; P, proestrus; day 0 is the day of stereotaxic surgery. (**f**) Mean ± SEM proestrous LH surge measured at 3, 4, and 5 pm EST in AVPV-AAV-*lacZ* and AVPV-AAV-*Esr1* mice (mice receiving g1 or g2 combined). (**g**) Mean ± SEM estradiol-induced LH surge measured at 9 am and 5 pm EST from AAV-*lacZ* and AAV-*Esr1* OVX + E mice (mice receiving g1 or g2 were combined).](elife-43999-fig3){#fig3}
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###### Specificity of the *Esr1* sgRNAs and off-target predictions by Feng Zhang's guide design tool software (<http://crispr.mit.edu>); Benchling analysis (<https://benchling.com/academic>) produced a subset of these results.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  sgRNA                 ^\*^Specificity score   & mismatches (MMs) between\   Gene                             ^\#^ Off-target score   Locus
                                                sgRNA and gene locus                                                                   
  --------------------- ----------------------- ----------------------------- -------------- ----------------- ----------------------- ----------------
   *Esr1*-g1            90                      4MMs \[2:9:11:12\]            NM_013870      *Smtn*            0.2                     chr11:+3417882

  4MMs \[5:10:13:19\]   NM_009728               *Atp10a*                      0.2            chr7:−66040030                            

  4MMs \[4:9:15:20\]    NM_023805               *Slc38a3*                     0.1            chr9:+107561207                           

  4MMs \[7:8:15:19\]    NM_001037764            *Rai1*                        0.1            chr11:+60003351                           

  4MMs \[3:10:13:14\]   NM_053193               *Cpsf1*                       0.1            chr15:−76426196                           

   *Esr1*-g2            73                      4MMs \[4:8:11:12\]            NM_001024560   *Snx32*           0.4                     chr19:+5495979

  4MMs \[2:4:5:16\]     NM_001194923            *Cldn18*                      0.3            chr9:+99617489                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------

^\*^Values range from 1 to 100 index to assess the specificity of a guide, with 100 being the most specific guide.

&4MMs \[2:9:11:12\] indicates nucleotides 2, 9, 11, 12 of the sgRNA do not match the 'off target' gene locus.

^\#^Off-target score values range from 0 to 100, with 100 being the value for the target *Esr1* gene.

Knockdown of ERα in AVPV kisspeptin neurons in adulthood does not affect estrous cycles but disrupts preovulatory and estradiol-induced LH surges {#s2-3}
-------------------------------------------------------------------------------------------------------------------------------------------------

We monitored the reproductive cycles of the mice injected with AAV-sgRNAs in the AVPV 12 days before and for up to eight weeks following surgery. Neither AVPV-AAV-*Esr1* guide (tested independently) nor the AVPV-AAV-*lacZ* disrupted reproductive cyclicity ([Figure 3e](#fig3){ref-type="fig"}), even in mice with a high rate of bilateral infection (\~80%). These mice entered proestrus at the same frequency in the last four weeks compared to the first four weeks (two weeks pre-surgery plus the first two weeks post-surgery, two-way repeated-measures ANOVA/Holm-Sidak, before vs after; g1, n = 3, 1.3 ± 0.1 vs 1.6 ± 0.1; g2, n = 4, 1.2 ± 0.1 1.4 ± 0.1; *lacZ* n = 4, 1.3 ± 0.2 vs 1.3±0.1, p\>0.1 for each paired comparison). To test for the occurrence of estradiol-positive feedback, we monitored both proestrous (preovulatory) and estradiol-induced LH surges in these mice. Surge data were similar for guide 1 and guide 2 and data from both guides were combined for group comparisons. Both proestrous and estradiol-induced LH surges were blunted after ERα knockdown ([Figure 3f,g](#fig3){ref-type="fig"}, two-way repeated-measures ANOVA/Holm-Sidak; f, *lacZ*, 3pm vs 5pm, p=0.04; *lacZ* vs *Esr1*, 4pm, p=0.006, 5pm, p\<0.0001, h, *lacZ* AM vs PM, p\<0.0001). There were fewer corpra lutea (CL) in mice with *Esr1* guides targeted to the AVPV (p\<0.05, guides 1 and 2 combined n = 6, 5.2 ± 2.1 CL/mouse, vs *lacZ* guide n = 5, 10.8 ± 0.4 CL/mouse, two-tailed paired Student's t test with Welch's correction, t = 2.598, df = 5.305). Of note, variation was high in the *Esr1* mice, with two looking similar to controls, two having fewer CL and two not having any CL. This suggests ovulation is disrupted in a substantial subpopulation of these mice but can proceed with the blunted LH surge in some animals.

Decreased excitability of AVPV kisspeptin neurons in AAV-*Esr1* knockdown mice {#s2-4}
------------------------------------------------------------------------------

To test if knockdown of ERα in adult AVPV kisspeptin neurons alters their intrinsic excitability, we recorded firing signatures of infected and uninfected cells in brain slices from AAV injected OVX + E mice. We again observed no difference between AVPV-AAV-*Esr1* g1 vs g2 and combined these data. Some cells were loaded with neurobiotin during recording for identification and ERα protein detected *post hoc* with immunofluorescence ([Figure 4a,c](#fig4){ref-type="fig"}, and IF post hoc portions of [Figure 4e--j](#fig4){ref-type="fig"}). Cells not infected with AVPV-AAV-*Esr1* and cells infected with either AVPV-AAV-*Esr1* guide but in which ERα protein was detected exhibited similar firing signatures in terms of DIB and rebound bursts ([Figure 4b,e,f](#fig4){ref-type="fig"}). In contrast, cells infected by AVPV-AAV-*Esr1* that had undetectable ERα protein had reduced burst firing compared to AVPV-AAV-*lacZ* or uninfected groups ([Figure 4e,f](#fig4){ref-type="fig"}, Chi-square, DIB, p=0.008, rebound bursts, p=0.0008; Fisher's exact *post hoc* test, DIB, *Esr1* vs *lacZ*, or vs uninfected, p≤0.03; rebound, *Esr1* vs *lacZ*, or vs uninfected p≤0.04; for other paired comparisons, p\>0.5). The firing signature of AAV-*Esr1-*infected cells with successful deletion of ERα was comparable to cells from KERKO mice (Chi-square, p\>0.9 for both DIB and rebound bursts). Cells that lost detectable ERα after AVPV-AAV-*Esr1* infection also produced fewer action potentials with current injection than cells infected with AAV-*lacZ* ([Figure 4d](#fig4){ref-type="fig"} left and center, two-way repeated-measures ANOVA/Holm-Sidak, *Esr1* vs *lacZ,* 20 pA, p=0.08; 30 to 50 pA p≤0.02). This difference is not attributable to passive properties ([Figure 1---figure supplement 1a,b](#fig1s1){ref-type="fig"}). The relationship between current injection and number of action potentials fired (input-output curve) in cells from KERKO and in AVPV-AAV-*Esr1* knockdown mice was only different at the highest level of current injected, with AVPV-AAV-*Esr1-*infected cells being less excitable ([Figure 4d](#fig4){ref-type="fig"}, right, two-way repeated-measures ANOVA/Holm-Sidak, 50 pA, p=0.01), despite no change in input resistance ([Figure 1---figure supplement 1a,b](#fig1s1){ref-type="fig"} KERKO vs AAV, p=0.08). Action potential properties from AVPV-AAV-*Esr1* knockdown cells with AVPV-AAV-*lacZ* control also differed. Specifically, loss of ERα led to decreased action potential rate of rise, a trend toward prolonged full-width half-maximum (FWHM), and hyperpolarized afterhyperpolarization potential (AHP) ([Figure 4--j](#fig4){ref-type="fig"}, two-tailed unpaired Student's *t*-test, h, p=0.02, j, p=0.0002; i, Mann-Whitney U-test, p=0.06).

![Decreased excitability of AVPV kisspeptin neurons in AVPV-AAV-*Esr1* knockdown mice.\
(**a--c**) whole-cell recording and immunofluorescence (IF) *post hoc* identification of ERα in recorded cells in OVX + E AVPV-AAV-*Esr1* infected mice. (**a**) visualization during recording; (**b**) representative depolarizing (+20 pA, magenta) and hyperpolarizing (−20 pA, black) firing signatures. (**c**) neurobiotin (blue) and ERα (red) staining after photobleaching of GFP and mCherry signals. From top to bottom: cells not infected by AVPV-AAV-*Esr1* and immunopositive for ERα; cells infected by AVPV-AAV-*Esr1* but still immunopositive for ERα; cells infected by AAV-*Esr1* and not immunopositive for ERα; cells infected by AVPV-AAV-*LacZ* and immunopositive for ERα. (**d**) left, input-output curves of infected cells with undetectable ERα in AAV-*Esr1* (third row in a-c, black circle), cells infected by *AVPV-*AAV-*lacZ* (bottom row in a-c, white circle, n = 14), and cells not infected by AAV (top row in a-c, orange circle); middle, input-output curves from a separate set of cells in which *Esr1* status was confirmed by single-cell qPCR *post hoc* (AAV-*Esr1* black circle; AAV-l*acZ,* white circle); right, input-output curve of AVPV-AAV-*Esr1* knockdown (black circle) vs KERKO (yellow circle) cells. (**e,f**) percent of cells exhibiting DIB (**e**) or rebound bursts (**f**). Cells per group is shown within or on top of the bar. (**g**), representative action potentials at the rheobase from *lacZ* vs *Esr1* infected cells. (**h--j**) individual values and mean ± SEM rate of rise (**h**) full width at half maximum (FWHM) (**i**) and afterhyperpolarization potential amplitude (AHP) (**j**). \*p\<0.05 vs all other groups; \# p\<0.05 vs uninfected.](elife-43999-fig4){#fig4}

In parallel, we performed whole-cell patch-clamp recording with single-cell PCR post hoc identification of *Esr1* mRNA on a separate set of cells (AVPV-AAV-*Esr1,* 10 cells from four mice; AVPV-AAV-*lacZ*, 9 cells from three mice; primers are in [Table 4](#table4){ref-type="table"}). A similar decrease in burst firing and action potential input-output curve was observed in *Esr1* mRNA negative cells as was observed in cells verified to have undetectable ERα protein by immunofluorescence ([Figure 4e,f](#fig4){ref-type="fig"}, Chi-square, DIB, p=0.04, rebound p=0.03; Fisher's exact *post hoc* test, DIB, *Esr1* vs *lacZ* p=0.03. *Esr1* vs uninfected, p=0.07; rebound, *Esr1* vs *lacZ* p=0.02; for other paired comparisons, p\>0.2). Absence of *Esr1* mRNA expression was again associated with decreased number of action potentials in response to current injection ([Figure 4d](#fig4){ref-type="fig"} middle, *Esr1* vs *lacZ,* p\<0.002 for 20 to 50 pA steps). Absence of *Esr1* mRNA, similar to loss of ERα protein, led to decreased action potential rate of rise, prolonged FWHM, and AHP ([Figure 4g--j](#fig4){ref-type="fig"} , two-tailed unpaired Student's *t*-test, h, p=0.02; i, p=0.006; j, p=0.02). Single-cell PCR analysis also indicates that a lower percent of AVPV-AAV-*Esr1* knockdown cells express *Kiss1* and a trend to increase in *Esr2* mRNA (AVPV-AAV-*Esr1,* 23 cells from four mice; AVPV-AAV-*lacZ*, 16 cells from three mice; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Interestingly, expression of the mRNA for progesterone receptor (*Pgr)* did not differ between groups ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), suggesting the estradiol-dependence of this gene may be paracrine regulated in the brain as in other tissues ([@bib22]). We also examined gene expression for several ion channels, but none showed any changes or patterns of expression among groups ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

10.7554/eLife.43999.013

###### Primer probes used for single-cell qPCR.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  IDT prime time\       Transcript   Forward 5\'−3\'          Reverse 5\'−3\'           Probe 5\'−3\'                 Amplicon\   Accession\     Location
  qPCR probe\                                                                                                         \           \              
  assay                                                                                                               (bp)        no.            
  --------------------- ------------ ------------------------ ------------------------- ----------------------------- ----------- -------------- ------------
  Mm.PT.58.42702897     *Cacna1g*    CTCAACTGTATCACCATCGCTA   AAGACTGCCGTGAAGATGT       CGCCCCAAAATTGACCCCCAC         101         NM_009783      4446--4546

  Mm.PT.58.15908160     *Cacna1h*    GACACTGTGGTTCAAGCTCT     TTATCCTCGC\               ACCTTGGTCTTCTTTTCATGCTCCTGT   122         NM_021415      5565--5686
                                                              TGCATTCTAGC                                                                        

  Mm.PT.58.9567566      *Cacna1i*    CATCACCTTCATCATCTGCCT    CCTCCAGCACAAAGACAGT       ACCAGCCTACATCCCTAGAGACAGC     125         NM_001044308   4914--5038

  Mm.PT.58.41764708     *Esr1*       GCTCCTTCTCATTCTTTCCCA    TCCAGGAGCAGGTCATAGAG      CCATGCCTTTGTTACTCATGTGCCG     108         NM_007956      1768--1865

  Mm.PT.58.16981577     *Esr2*       CCTCCTGATGCTTCTTTCTCAT   TCGAAGCGTGTGAGCATTC       TCCATGCCCTTGTTACTGATGTGCC     133         NM_207707      1829--1961

  Mm.PT.58.30501833     *Hcn1*       GCGTTATCACCAAGTCCAGTA    CAGTAGGTATCAGCTCGGACA     CTCCGAAGTAAGAGCCATCTGTCAGC    115         NM_010408      1913--2027

  Mm.PT.58.7963736      *Hcn2*       CTTCACCAAGATCCTCAGTCTG   GGTCGTAGGTCATGTGGAAA      TGCGGCTATCACGGCTCATCC         98          NM_008226      935--1032

  Mm.PT.58.7999585      *Hcn3*       GCCTCACTGATGGATCCTACT    TCAAGCACCGCATTGAAGT       ACCTATTGTCGCCTCTACTCGCTCA     130         NM_008227      1546--1675

  Mm.PT.58.43863085     *Hcn4*       GCTGATGGCTCCTATTTTGGA    TCATTGAAGTTGTCCACGCT      AAGTATCCGCTCTGACGCTGGC        116         NM_001081192   2614--2729

  Mm.PT.45.16269514     *Kiss1*      CTGCTTCTCCTCTGTGTCG      TTCCCAGGCATTAACGAGTTC.    CGGACTGCTGGCCTGTGGAT          105         NM_178260      66--170

  Mm.PT.47.10254276     *Pgr*        CGCCATACCTTAACTACCTGAG   CCATAGTGACAGCCAGATGC      AGATTCAGAAGCCAGCCAGAGCC       124         NM_008829      2230--2353

  Mm.PT.51.17048009.g   *Syn1*       CTTGAGCAGATT GCCATGTC    ACCTCAATAATGTGATCCCTTCC   ACGTGTCTACCCACAACTTGTACCTG    131         NM_013680      1159--1289

  Mm.PT.58.33106186     *Th*         CCCTACCAAGATCAAACCTACC   CTGGATACGAGAGGCATAGTTC    TGAAGCTCTCTGACACGAAGTACACCG   96          NM_009377      1298--1393
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

Knockdown of ERα in arcuate kisspeptin neurons in adulthood disrupts estrous cycles {#s2-5}
-----------------------------------------------------------------------------------

To examine the role of estradiol feedback on arcuate kisspeptin neurons, we delivered the AAV-sgRNAs bilaterally to the arcuate region to knockdown ERα in these cells ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}); these groups are referred to as Arc-AAV-*Esr1* or Arc-AAV-*lacZ*. The infection rate for Arc-AAV-*Esr1* was 92 ± 3% ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}, n = 3 *Esr1*-guide1 96 ± 2%; n = 3 *Esr1*-guide2 86 ± 2%) and only 34 ± 3% of KNDy neurons expressed ERα post infection ([Figure 5a](#fig5){ref-type="fig"} n = 3 *Esr1*-g1, 38 ± 0.3%; n = 3 *Esr1*-g2, 30 ± 5%). In mice that received Arc-AAV-*lacZ*, the infection rate was comparable ([Figure 5a](#fig5){ref-type="fig"} n = 3, 94 ± 3%), and 92 ± 1% of KNDy neurons expressed ERα, similar to control mice ([@bib26]). Reproductive cycles were monitored for 12 days before and for up to eight weeks following surgery. In contrast to mice with Arc-AAV-*Esr1* targeted to the AVPV region, mice with the same virus targeted to the arcuate began exhibiting disrupted cyclicity three to four weeks post surgery ([Figure 5b](#fig5){ref-type="fig"}). These mice entered proestrus less frequently after surgery than before (two weeks pre-surgery plus the first two weeks post-surgery, [Figure 5d](#fig5){ref-type="fig"}, two-way repeated-measures ANOVA/Holm-Sidak, g1, p=0.002, g2, p=0.03). There was no difference in LH pulse frequency measured on the day of estrus or mean levels between Arc-AAV-*Esr1* vs Arc-AAV-*lacZ* injected mice on estrus ([Figure 5c,e,f](#fig5){ref-type="fig"}). Notably, LH response to kisspeptin and to GnRH was reduced in Arc-AAV-*Esr1* mice ([Figure 5g](#fig5){ref-type="fig"}, two-way repeated measures ANOVA/Holm-Sidak, *lacZ*, control vs kisspeptin or GnRH, p\<0.001; *Esr1* vs *lacZ* for kisspeptin and GnRH both, p≤0.002).

![Deletion of ER in arcuate kisspeptin neurons.\
(**a**) Arc-AAV-*lacZ* and Arc-AAV-*Esr1* (g1 or g2) were bilaterally delivered to arcuate region (see [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Brain sections were processed to detect GFP (green), mCherry (red) and ERα (black). Arc-AAV-*Esr1* infected arcuate kisspeptin neurons exhibit decreased ERα expression compared to Arc-AAV-*lacZ* infected cells (bottom panel of each pair, white arrows indicate ERα-negative, magenta arrows indicate ERα-positive infected cells). (**b**) representative reproductive cycles of mice that received Arc-AAV-*lacZ*, -*Esr1* g1 or g2; E, estrus; D, diestrus; P, proestrus. Day 0 indicates the day of stereotaxic surgery. (**c**) pulsatile LH release in Arc-AAV-*lacZ*, -*Esr1* g1 or g2 mice, \# indicate pulse detected by Cluster analysis ([@bib51]). (**d**) Mean ± SEM days/week in proestrus before (from day −12 to day 14) and after infection (day 29 to day 56) in mice receiving Arc-AAV-*lacZ, -Esr1* g1 or g2. (**e**) Individual values and mean ± SEM LH pulses/h. (**f**) Individual means and mean ± SEM mean LH over the entire pretreatment sampling period. (**g**) Mean ± SEM LH before (con) and 15 min after kisspeptin (kiss) injection (left) and before (con) and 15 min after GnRH injection (right). \*p\<0.05.](elife-43999-fig5){#fig5}

Knockdown of ERα in arcuate kisspeptin neurons in adulthood increase ionotropic glutamatergic transmission to these cells but does not alter their short-term spontaneous firing rate {#s2-6}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Arcuate kisspeptin neurons are postulated to form an interconnected network that is steroid sensitive and utilizes glutamatergic transmission at least in part for intranetwork communication ([@bib41]). We thus hypothesized that loss of ERα specifically from arcuate kisspeptin neurons would increase their spontaneous firing rate and increase glutamatergic transmission to these cells, similar to what is observed in these cells in KERKO mice ([@bib55]). As Arc-AAV-*Esr1* knockdown mice spend the most time in estrus, similar to KERKO mice, we used estrus as the reproductive stage to examine the short-term (\~10 min) firing frequency of these neurons and AMPA-mediated excitatory glutamatergic postsynaptic currents (EPSCs). The firing frequency of Arc-AAV-*Esr1* infected cells was not different from Arc-AAV-*lacZ* infected cells ([Figure 6a,b](#fig6){ref-type="fig"}, Mann-Whitney U-test, p=0.14) even though there tends to be more cells firing at \>1 Hz in the Arc-AAV-*Esr1* group compared to the Arc-AAV-*lacZ* group ([Figure 6c](#fig6){ref-type="fig"}, Fisher's exact test, *Esr1* vs *lacZ*, p=0.07). In contrast, the frequency and amplitude of glutamatergic EPSCs in arcuate kisspeptin cells in Arc-AAV-*Esr1* infected mice was greater than in the Arc-AAV-*lacZ* group ([Figure 6d,e,f](#fig6){ref-type="fig"}, two-tailed unpaired Student's t-test, frequency p=0.0007, amplitude p=0.014).

![*Esr1* knockdown in arcuate kisspeptin neurons alters cellular physiology.\
(**a**) Representative extracellular recordings of firing rate. (**b**), (**c**) individual values and mean ± SEM firing rate (**b**) and percent of cells with firing rate \>1 Hz (**c**); cells per group shown in bars. (**d**) representative whole-cell recordings of EPSCs. (**e, f**) individual values and mean ± SEM of EPSC frequency (**e**) and amplitude (**f**). \*p\<0.05.](elife-43999-fig6){#fig6}

Discussion {#s3}
==========

This study examined the roles of two hypothalamic kisspeptin neuronal populations in mediating estradiol feedback from cellular, molecular and whole-body physiology perspectives. We utilized both conventional kisspeptin-specific ERα knockout mice (KERKO) and CRISPR-Cas9-based viral vector-mediated knockdown of *Esr1*. The latter approach allows both temporal control and nucleus-specific manipulations to distinguish the role of ERα within each population in negative and positive feedback regulation of LH release and neurobiological properties ([Figure 7](#fig7){ref-type="fig"}).

![Schematic diagram of estradiol feedback regulation on ERα in AVPV and arcuate kisspeptin neurons in adulthood.\
Knockdown of ERα in AVPV kisspeptin neurons blunted LH surge but did not alter reproductive cyclicity whereas knockdown of ERα in arcuate kisspeptin neurons disrupted the cyclicity.](elife-43999-fig7){#fig7}

AVPV kisspeptin neurons are postulated to convey estradiol positive feedback signals to generate the GnRH surge. Consistent with this postulate, these neurons are more excitable during positive feedback and also receive increased glutamatergic transmission ([@bib39]; [@bib58]; [@bib54]; [@bib55]). AVPV kisspeptin cells in both KERKO and AVPV-AAV-*Esr1* models are less excitable compared to controls, firing fewer bursts and single action potentials in response to the same current injection. Results from the AVPV-AAV-*Esr1* model support and extend data from KERKO mice and provide evidence towards accepting the hypothesis that the role of ERα in shifting excitability is activational, independent of its role in the development of these cells ([@bib31]).

Kisspeptin expression in AVPV cells is estradiol activated and fewer cells expressing *Kiss1* mRNA are detected in this region in KERKO mice ([@bib18]). In AVPV-AAV-*Esr1* mice with adult knockdown, we also observed fewer cells express *Kiss1* mRNA compared to AVPV-AAV-*lacZ* mice, further supporting an activational role for estradiol in the adult physiology of these cells. The inability to sense estradiol through ERα in AVPV kisspeptin neurons may reduce production and release of kisspeptin and ultimately impair the downstream GnRH/LH surge. This could explain the blunted LH surges in AVPV-AAV-*Esr1* injected mice. *Esr1* knockdown in the AVPV, however, did not alter reproductive cyclicity monitored by changes in vaginal cytology. Vaginal cytology reflects circulating steroids, in particular estradiol. Of note, only some of these mice had evidence of typical ovulation monitored by the number of corpra lutea. It is possible that sufficient estradiol is produced during these cycles to induce vaginal cytology, but not to trigger an LH surge. It is important to point out, however, that estradiol-induced LH surges, in which an established dose of estradiol was provided to the mouse, were also blunted in AVPV-AAV-*Esr1* mice. This latter observation suggests that inappropriate response of the neuroendocrine system to estradiol is, at least in part, responsible for the blunting of the LH surge. With regard to the continuation of estrous cycles in the AVPV-AAV-*Esr1* mice, typical function of the remaining ERα-positive AVPV kisspeptin neurons may be sufficient to drive maintain cyclicity. Alternatively, cyclicity and the associated changes in sex steroids may be controlled by other cells that express ERα. Of interest, stress or neuronal androgen receptor KO can similarly disrupt the LH surge without a change in estrous cyclicity ([@bib52]; [@bib53]).

In support of a non-AVPV kisspeptin neuronal population being a primary driver of estrous cyclicity, several reproductive phenotypes of KERKO and AVPV-targeted ERα knockdown mice are different. KERKO mice tend to exhibit prolonged vaginal cornification and enlarged uteri, neither of which were observed in mice in which AAV-*Esr1* infection was targeted to the AVPV ([Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}). In contrast, prolonged estrus and enlarged uteri were observed in mice in which Arc-AAV-*Esr1* infection was targeted to arcuate kisspeptin neurons. These latter neurons have been postulated to play a role in generating episodic GnRH output. Changes in episodic GnRH frequency drive gonadotropins and thus follicle development and steroidogenesis, including the estradiol rise, which triggers positive feedback and changes in vaginal cytology. Long-term firing output of arcuate kisspeptin neurons in brain slices is episodic and steroid modulated ([@bib50]), and activation of these cells in vivo generates a pulse of LH release ([@bib8]). Further evidence comes from *Tac2*-specific ERα KO mice, in which ERα is primarily deleted from the arcuate, not the AVPV, kisspeptin population. These mice also exhibit prolonged vaginal cornification ([@bib18]). We thus hypothesize that ERα in arcuate kisspeptin neurons contributes to maintaining pulsatile LH release and mediates central estradiol negative feedback.

Consistent with this postulate, partial (\~65%) adult knockdown of ERα in these cells altered the reproductive cycle. As KERKO mice exhibit increased LH-pulse frequency, we were initially surprised we did not observe differences in pulse frequency or mean LH levels in mice receiving Arc-AAV-*Esr1*. This may be attributable to single housing conditions in the present experiment, which may make mice prone to stress despite more than four weeks of handling before sampling. It is also possible that the pulse frequency during diestrus differs between Arc-AAV-*Esr1* and Arc-AAV-*lacZ* mice. Despite this lack of statistical difference in LH-pulse frequency, ERα knockdown mice had a markedly reduced response to IP injection of both kisspeptin and GnRH, similar to KERKO mice ([@bib55]). This suggests loss of ERα function in arcuate kisspeptin neurons may disrupt GnRH neuronal response to kisspeptin and/or the pituitary response to GnRH. This could arise from a disruption of negative feedback leading to overstimulation and thus desensitization of the hypothalamo-pituitary-gonadal axis or blunting of the response to administered neuropeptides.

Dissection of the electrophysiological properties of arcuate kisspeptin neurons revealed that glutamatergic transmission to these neurons was elevated when ERα is knocked down. This indicates the connectivity of these cells remains plastic even after puberty. The observation that targeted reduction of ERα in arcuate kisspeptin neurons increases glutamatergic transmission further suggests interconnections among these cells provide many of their glutamatergic inputs. Given this, it is intriguing that the short-term firing rate of these cells was not increased, although there was a strong trend toward a greater percent of higher frequency cells. The lack of change in mean firing rate may reflect the partial deletion of ERα in this population, with lower firing rate being preserved in cells with ERα, and elevated EPSC frequency arising at least in part from the high firing cells. It is also possible that long-term firing patterns of these Arc-AAV-*Esr1* infected arcuate kisspeptin neurons, which may be associated with episodic neuroendocrine activity, are disrupted. These data support the idea that glutamatergic inputs to arcuate kisspeptin neurons play an important role on maintaining normal reproductive function.

Although the CRISPR-Cas9-based knockdown approach allows spatial and temporal control, it too has caveats. For example, sgRNAs may have off-target actions on other regions of the genome beyond the sites predicted by the design software ([@bib2]). To address this, we independently tested two sgRNAs that target *Esr1* to address the possible off-target effects among groups. We did not observe any differences between *Esr1* guide1 and guide2 groups. This suggests the phenotypes observed are primarily attributable to the deletion of ERα. Because of the nature of the nonhomologous end joining repair machinery activated after CRISPR-Cas9-initiated cuts, *Esr1* gene editing in each cell varies. It is difficult to assess each individual neuron to test if mutations at other genes are potentially involved in changes of biophysical properties. Despite these variables, in the present study the systemic and cellular phenotypes in *Esr1* guide1 vs guide2 infected mice were quite consistent.

In conclusion, utilizing CRISPR-Cas9 AAV, we were able to successfully knockdown ERα in specific populations of kisspeptin neurons in adult female mice. Knockdown in each population recapitulated part of the KERKO model and furthers our understanding the role ERα in that population in regulating estradiol feedback.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\    Designation             Source or reference        Identifiers                                                 Additional information
  (species) or\                                                                                                                   
  resource                                                                                                                        
  ---------------- ----------------------- -------------------------- ----------------------------------------------------------- ------------------------
  Mus musculus,\   Kiss1-ires-Cre          PMID 26862996                                                                          Dr. Martin Myers,\
  C57BL/6J                                                                                                                        University of Michigan

  Mus musculus,\   Esr1 loxp               PMID 17785410                                                                          Dr. Martin Myers,\
  C57BL/6J                                                                                                                        University of Michigan

  Mus musculus,\   Kiss1-cre               Dr. Carol Elias/Jackson\   JAX 023426                                                  
  C57BL/6J                                 Labs                                                                                   

  Mus musculus,\   Cas9-stop loxp          Jackson Labs               Jax 024858;\                                                
  C57BL/6J                                                            RRID:[IMSR_JAX:024858](https://www.jax.org/strain/024858)   

  Mus musculus,\   Rosa26-EYFP             Jackson Labs               Jax 006148;\                                                
  C57BL/6J                                                            RRID:[IMSR_JAX:006148](https://www.jax.org/strain/006148)   

  Mus musculus\    C2C12 myoblast          ATTC                       Cat \# CRL 1772                                             Dr. Daniel Michele,\
  myoblast, C3H                                                                                                                   University of Michigan

  Antibody         rabbit anti-ERα         Millipore                  \#06-935                                                    dil. 1:10000

  Antibody         rat anti-mCherry        Invitrogen                 M11217                                                      dil. 1:5000

  Antibody         chicken anti-GFP        Abcam                      ab13970                                                     dil. 1:2000

  Recombinant\     AAV8-hsyn-dio-sg\       this paper                 Custom Order                                                UNC-viral core
  DNA reagent      RNA_lacZ-mCherry                                                                                               

  Recombinant\     AAV8-hsyn-dio-sg\       this paper                 Custom Order                                                UNC-viral core
  DNA reagent      RNAEsr1_g1-mCherry                                                                                             

  Recombinant\     AAV8-hsyn-dio-sg\       this paper                 Custom Order                                                UNC-viral core
  DNA reagent      RNAEsr1_g2-mCherry                                                                                             

  Recombinant\     plasmid\                this paper                 built on lentiCRISPRv2;\                                    
  DNA reagent      LentiV2-sgRNA-Esr1_g1                              Addgene Cat \#52961                                         

  Recombinant\     plasmid\                this paper                 built on lentiCRISPRv2;\                                    
  DNA reagent      LentiV2-sgRNA-Esr1_g2                              Addgene Cat \#52961                                         

  Recombinant\     plasmid\                this paper                 built on lentiCRISPRv2;\                                    
  DNA reagent      LentiV2-sgRNA-lacZ                                 Addgene Cat \#52961                                         

  Commercial\      ABC amplification       Vector Laboratories        Cat \# PK-6100                                              
  assay or kit                                                                                                                    

  Chemical\        CNQX                    Sigma-Aldrich              Cat \# 1045                                                 
  compound, drug                                                                                                                  

  Chemical\        APV                     Tocris                     Cat \# 0106                                                 
  compound, drug                                                                                                                  

  Chemical\        picrotoxin              Sigma-Aldrich              Cat \# P1675                                                
  compound, drug                                                                                                                  

  Chemical\        TTX                     Tocris                     Cat \# 1069                                                 
  compound, drug                                                                                                                  

  Chemical\        10% Neutral\            Fisher Scientific          Cat \# 22899402                                             
  compound, drug   Buffered Formalin                                                                                              

  Chemical\        Hydrogen Peroxide       Sigma                      Cat \# 216763                                               
  compound, drug                                                                                                                  

  Chemical\        LHRH                    Bachem                     Cat \# H4005                                                
  compound, drug                                                                                                                  

  Chemical\        kisspeptin              Phoenix                    Cat \# 048-56                                               
  compound, drug                                                                                                                  

  Chemical\        Neurobiotin             Vector Labs                Cat \# SP-1120                                              
  compound, drug                                                                                                                  

  Software,\       Igor Pro                Wavemetrics                <https://github.com/defazio2/LWeLifeRepo>                   
  algorithm                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

The University of Michigan Institutional Animal Care and Use Committee approved all procedures. Adult female mice (60--150 days) were used. Mice were provided with water and Harlan 2916 chow (VetOne) *ad libitum* and were held on a 14L:10D light cycle (lights on 0400 Eastern Standard Time). To delete ERα specifically from all kisspeptin cells ([@bib55]), mice with the *Cre* recombinase gene knocked-in after the *Kiss1* promoter (*Kiss1*-ires-Cre mice, [@bib10]) were crossed with mice with a floxed *Esr1* gene, which encodes ERα (ERα floxed mice) ([@bib18]). The expression of Cre recombinase mediates deletion of ERα in kisspeptin cells (KERKO mice). To visualize kisspeptin neurons for recording, mice heterozygous for both Kiss-Cre and floxed ERα were crossed with Cre-inducible YFP mice. Crossing mice heterozygous for all three alleles yielded litters that contained some mice that were homozygous for floxed ERα and at least heterozygous for both *Kiss1*-Cre and YFP; these were used as KERKO mice. Littermates of KERKO mice with wild-type *Esr1, Kiss1*-Cre YFP (heterozygous or homozygous for either Cre or YFP) were used as controls; no differences were observed among these controls and they were combined.

To generate kisspeptin-specific *S. pyogenes* Cas9 (Cas9)-expressing mice, mice with the *Cre* recombinase gene knocked-in after the *Kiss1* promoter (*Kiss1-Cre* mice) were crossed with mice that have Cre recombinase-dependent expression of CRISPR-associated protein 9 (Cas9) endonuclease, a 3X-FLAG epitope tag and eGFP directed by a CAG promoter. KERKO mice have disrupted estrous cycles with persistently cornified vaginal cytology typical of estrus; we thus used females in estrus as controls. Estrous cycle stage was determined by vaginal lavage. To examine the role of circulating estradiol, mice were ovariectomized (OVX) under isoflurane anesthesia (Abbott) and were either simultaneously implanted with a Silastic (Dow-Corning) capsule containing 0.625 µg of estradiol suspended in sesame oil (OVX +E) or not treated further (OVX) ([@bib5]). Bupivacaine (0.25%, APP Pharmaceuticals) was provided local to incisions as an analgesic. These mice were studied 2-3 days after surgery. Mice for electrophysiology were sacrificed at the time of estradiol positive feedback in the late afternoon ([@bib5]). For free-floating immunochemistry staining, mice were perfused at 1700 EST 2-3d post OVX +E surgery at the expected peak of the estradiol-induced LH surge.

sgRNA design {#s4-2}
------------

For Cas9 target selection and generating single guide RNAs (sgRNA), 20-nt target sequences were selected to precede a 5'NGG protospacer-adjacent motif (PAM) sequence. To minimize off-targeting effects and maximize sgRNA activity, two CRISPR design tools were used to evaluate sgRNAs ([@bib43]; [@bib13]) targeting the first coding exon of mouse *Esr1*. The two best candidates were selected based on lowest predicted off-target effects and highest activity. The target sequence for guide 1 is 5'-CACTGTGTTCAACTACCCCG-3' (referred to as g1) and the target sequence for guide 2 is 3'-CTCGGGGTAGTTGAACACAG-5' (referred to as g2). Because g1 and g2 were similarly effective in *Esr1* knockdown and effects on cycles, mice were combined for physiology studies. Control sgRNA sequence was designed to target *lacZ* gene from *Escherichia coli* (target sequence: 5'-TGCGCAGCCTGAATGGCGAA −3').

In vitro validation of sgRNAs {#s4-3}
-----------------------------

Mycoplasma-free C2C12 mouse myoblast cells (generous gift of Dr. Daniel Michele, University of Michigan) were grown in DMEM containing 10% FBS (Thermo Fisher) at 37°C in 5% CO2. Each individual sgRNA was introduced to BsmBI site of the lentiCRISPRv2 construct. Cells were co-transfected with one of the lentiCRISPRv2 plasmids containing sgRNAs and a standard GFP plasmid construct ([@bib42]) using Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions. Cells were selected for \~4 weeks with medium containing 1 μg/mL puromycin. Selected cells were harvested, DNA isolated using the Qiagen DNA Extraction Kit, and sequenced with primers for *Esr1*.

AAV vector production {#s4-4}
---------------------

To construct the AAV plasmid, a mCherry-U6 promoter-sgRNA scaffold segment was synthesized by Integrated DNA Technologies (IDT). After PCR amplification, the ligation product containing mCherry-U6 promoter-sgRNA scaffold was cloned in reverse orientation into a hSyn (human Synapsin 1) promoter driven *Cre*-inducible AAV vector backbone ([@bib15]). The individual sgRNAs (with an extra G added to the 5\'-end of each sgRNA to increase guide efficiency \[[@bib13]\]) were then inserted into a designed SapI site between U6 promoter and sgRNA scaffold component. All three AAV viral vectors were prepared in AAV8 serotype at University of North Carolina Vector Core.

Stereotaxic injections {#s4-5}
----------------------

Kiss1Cre/Cas9-GFP female animals (\>2 mo) were checked for estrous cycles for \>10 days before surgery; only mice with regular 4--5 day cycles were used. Mice were anesthetized with 1.5--2% isoflurane. AVPV injections were targeted to 0.55 mm posterior to Bregma, ±0.2 mm lateral to midline, and 4.7 and 4.8 mm ventral to dura. Arcuate injections were targeted to 1.5--1.7 mm posterior to Bregma, ±0.2 mm lateral to midline, and 5.9 mm ventral to dura. 100 nl virus injected bilaterally at the target coordinates at \~5 nl/min. The pipette was left in place for 5 min after injection to allow viral diffusion into the brain. Carprofen (Zoetis, Inc., 5 mg/kg, sc) was given before and 24 hr after surgery to alleviate postsurgical pain. Estrous cycle monitoring continued after surgery for up to 8 weeks. Stereotaxic hits were defined as ≥70% infection rate in both hemispheres; only bilateral hits were included for in vivo evaluation of reproductive parameters.

Perfusion and free-floating immunohistochemistry {#s4-6}
------------------------------------------------

Mice were anesthetized with isoflurane and then transcardially perfused with PBS (15--20 mL) then 10% neutral-buffered formalin for 10 min (\~50 mL). Brains were placed into the same fixative overnight, followed by 30% sucrose for ≥24 hr for cryoprotection. Sections (30 μm, four series) were cut on a cryostat (Leica CM3050S) and stored at −20°C in antifreeze solution (25% ethylene glycol, 25% glycerol in PBS). Sections were washed with PBS, treated with 0.1% hydrogen peroxide, and then placed in blocking solution (PBS containing 0.1% TritonX-100, 4% normal goat serum, Jackson Immunoresearch) for 1 hr at room temperature, then incubated with rabbit anti-ERα (\#06--935, Millipore, 1:10,000; this antibody recognizes the C-terminus of ERα.) in blocking solution 48 hr at 4°C. Sections were washed then incubated with biotinylated anti-rabbit antibody (Jackson Immunoresearch, 1:500) followed by ABC amplification (Vector Laboratories, 1:500) and nickel-enhanced diaminobenzidine (Thermo Scientific) reaction (4.5 min). Sections were washed with PBS and incubated overnight with chicken anti-GFP (ab13970, Abcam, 1:2000) and rat anti-mCherry (M11217, Invitrogen, 1:5000) in blocking solution. The next day, sections were washed and incubated with Alexa 594-conjugated anti-rat and Alexa 488-conjugated anti-chicken antibodies for 1 hr at room temperature (Molecular Probes, 1:500). Sections were mounted and coverslipped (VWR International 48393 251). Images were collected on a Zeiss AXIO Imager M2 microscope, and the number of immunoreactive GFP only, GFP/mCherry, and GFP/mCherry/ERα cells were counted in the injected region. The other kisspeptin region in the hypothalamus was examined and no infection of kisspeptin cell bodies was observed.

Brain slice preparation {#s4-7}
-----------------------

All solutions were bubbled with 95%O~2~ and 5%CO~2~ for ≥15 min before exposure to tissue and throughout experiments. Brains were rapidly removed 1.5--2 hr before lights off and placed in ice-cold sucrose saline solution containing (in mM): 250 sucrose, 3.5 KCl, 25 NaHCO~3~, 10 D-glucose, 1.25 Na~2~HPO~4~, 1.2 MgSO~4~, and 3.8 MgCl~2~. Coronal slides (300 μm) were made with a Leica VT1200S. Slices were incubated in a 1:1 mixture of sucrose-saline and artificial cerebrospinal fluid (ACSF) containing (in mM): 135 NaCl, 3.5 KCl, 26 NaHCO~3~, 10 D-glucose, 1.25 Na~2~HPO~4~, 1.2 MgSO~4~, 2.5 CaCl~2~ for 30 min at room temperature. Slices were then transferred to 100% ACSF at room temperature for ≥30 min before recording. Slices were used within 6 hr of preparation.

Electrophysiology recordings {#s4-8}
----------------------------

Slices were transferred to a recording chamber and perfused with oxygenated ACSF (3 mL/min) and heated by an in-line heater (Warner Instruments) to 30 ± 1°C. GnRH-GFP neurons were identified by brief illumination at 470 nm using an upright fluorescence microscope Olympus BX51W1. Recording pipettes were pulled from borosilicate glass (type 7052, 1.65 mm outer diameter and 1.12 mm inner diameter; World Precision Instruments, Inc) using a P-97 puller (Sutter Instruments) to obtain pipettes with a resistance of 2--3.5 MΩ. Recordings were performed with an EPC-10 dual-patch clamp amplifier and Patchmaster acquisition software (HEKA Elektronik). Recorded cells were mapped to a brain atlas ([@bib37]) to determine if cell location was related to response to treatment. No such correlation was observed in this study.

Extracellular recordings {#s4-9}
------------------------

Extracellular recordings were used to characterize firing rate as they maintain internal milieu and have minimal impact neuronal firing rate ([@bib35]; [@bib1]). Recordings were made with receptors for ionotropic GABA~A~ and glutamate synaptic transmission antagonized (100 µM picrotoxin, 20 µM D-APV \[D-(−)−2-amino-5-phosphonopentenoic acid\], 10 µM CNQX \[6-cyano-7-nitroquinoxaline\]). Pipettes were filled with HEPES-buffered solution containing (in mM): 150 NaCl, 10 HEPES, 10 D-glucose, 2.5 CaCl~2~, 1.3 MgCl2, and 3.5 KCl (pH = 7.4, 310 mOsm), and low-resistance (22 ± 3 MΩ) seals formed between the pipette and neuron after first exposing the pipette to the slice tissue in the absence of positive pressure. Recordings were made in voltage-clamp mode (0 mV pipette holding potential) and signals acquired at 20 kHz and filtered at 10 kHz. Resistance of the loose seal was checked frequently during the first 3 min of recordings to ensure a stable baseline, and also before and after a subsequent 10 min recording period; data were not used if seal resistance changed \>30% or was \>25 MΩ. The first 5 min of this 10-min recording were consistently stable among cells and were thus used for analysis.

Whole-cell recordings {#s4-10}
---------------------

For whole-cell patch-clamp recordings, three different pipette solutions were used depending on the goal. Most recordings were done with a physiologic pipette solution containing (in mM): 135 K gluconate, 10 KCl, 10 HEPES, 5 EGTA, 0.1 CaCl~2~, 4 MgATP and 0.4 NaGTP, pH 7.2 with NaOH, 302 ± 3 mOsm. A similar solution containing 10 mM neurobiotin was adjusted to similar osmolarity. A solution in which cesium gluconate replaced potassium gluconate was used to reduce potassium currents and allow better isolation of calcium currents. Membrane potentials reported were corrected online for liquid junction potential of −15.7 mV, same among all solutions ([@bib3]).

After achieving a minimum 1.6 GΩ seal and the whole-cell configuration, membrane potential was held at −70 mV between protocols during voltage-clamp recordings. Series resistance (R~s~), input resistance (R~in~), holding current (I~hold~) and membrane capacitance (C~m~) were frequently measured using a 5 mV hyperpolarizing step from −70 mV (mean of 16 repeats). Only recordings with R~in~ \>500 MΩ, I~hold~−40 to 10 pA and R~S~ \<20 MΩ, and stable C~m~ were accepted. R~s~ was further evaluated for stability and any voltage-clamp recordings with ∆R~s~ \>15% were excluded; current-clamp recordings with ∆R~s~ \>20% were excluded. There was no difference in I~hold~, C~m~, or R~s~ among any comparisons.

For current-clamp recordings, depolarizing and hyperpolarizing current injections (−50 to +50 pA, 500 ms, 10 pA increments) were applied from an initial membrane potential of −71 ± 2 mV, near the resting membrane potential of these cells ([@bib11]).

For voltage-clamp recordings of excitatory postsynaptic currents (EPSCs), membrane potential was held at −68 mV, the reversal potential for GABA~A~-receptor mediated currents, and ACSF contained picrotoxin (100 μM), and D-APV (20 μM).

For voltage-clamp recordings of I~T~, ACSF containing antagonists of ionotropic GABA~A~ and glutamate receptors was supplemented with TTX (2 µM) and the Cs-based pipette solution was used. Two voltage protocols were used to isolate I~T~ as reported ([@bib54]). First, total calcium current activation was examined. Inactivation was removed by hyperpolarizing the membrane potential to −110 mV for 350 ms (not shown in figures). Next, a 250 ms prepulse of −110 mV was given. Then membrane potential was varied in 10 mV increments for 250 ms from −110 to −30 mV. Finally, test pulse of −40 mV for 250 ms was given. From examination of the current during the test pulse, it was evident that no sustained (high-voltage activated, HVA) calcium current was activated at potentials more hyperpolarized than −40 mV. To remove HVA contamination from the step to −30 mV, a second protocol was used in which removal of inactivation (−110 mV, 350 ms) was followed by a 250 ms prepulse at −40 mV, then a step for 250 ms at −30 mV and finally a test pulse of −40 mV for 250 ms. I~T~ was isolated by subtracting the trace following the −40 mV prepulse from those obtained after the −110 mV prepulse for the depolarized variable step to −30 mV; raw traces from the initial voltage protocol were used without subtraction for variable steps from −110 mV to −40 mV because of the lack of observed activation of HVA at these potentials. Activation of I~T~ was assessed from the resulting family of traces by peak current during the variable step phase. Inactivation of I~T~ was assessed from the peak current during the final −40 mV test pulse.

*Post hoc* identification of ERα {#s4-11}
--------------------------------

The pipette solution containing neurobiotin was used for recordings cells from AAV-injected mice. An outside-out patch was formed after recording to reseal the membrane and the location of cells was marked on a brain atlas ([@bib37]). The brain slices were fixed overnight in 10% formalin at 4°C and changed to PBS. Slices were photo-bleached with a UV illuminator for \~72 hr and checked to ensure no visible fluorescent signal was observed. Slices were then placed in blocking solution for 1 hr, then incubated with rabbit anti-ERα for 48 hr at 4°C. Slices were washed and then incubated with Alexa 594-conjugated anti-rabbit and Alexa 350-conjugated neutravidin for 2 hr at room temperature (Molecular Probes, 1:500). Slices were mounted, coverslipped and imaged as above. Cells with neurobiotin-labeling were examined for ERα-immunoreactivity.

*Single-cell PCR* Cells for single cell PCR were collected as previously described ([@bib44]). Patch pipettes (2--3 MΩ) were filled with 5--8 μL of an RNase free solution containing (in mM): 135 K-gluconate, 10 KCl, 10 HEPES, 5 EGTA, 4.0 Mg-ATP, 0.4 Na-GTP, and 1.0 CaCl~2~ (pH 7.3, 305 mOsm). Additionally, just before use 1 U/µL Protector RNase Inhibitor (Roche, Indianapolis, IN) was added to the pipette solution. Single-cell RNA was harvested from the target cells in whole-cell configuration after recording membrane response in current-clamp; cytoplasm was aspirated into the pipette and expelled into a 0.2 mL tube containing reverse transcriptase buffer (Superscript Vilo cDNA Synthesis Kit, Invitrogen/ThermoFisher), volume was adjusted to 20 µL with molecular grade water. Cell contents were reverse transcribed following manufacturer's instructions. False harvests, in which the pipette was lowered into the slice preparation but no aspiration of cell contents occurred, were used to estimate background contamination. These were performed on each recording day. Additionally, a standard curve of mouse hypothalamic RNA (1, 0.1, 0.01, 0.001 ng/μL final concentration) and a water blank (negative control) were reverse transcribed. An equivalent volume of water or patch solution was reverse transcribed as a negative control. Single-cell cDNA, controls, and the standard curve were preamplified for 15 cycles using TaqMan PreAmp Master Mix (Invitrogen/ThermoFisher) as previously described ([@bib17]). Quantitative PCR was performed using 5 μL of diluted preamplified DNA (1:10) per reaction, in duplicate, for 50 cycles (TaqMan Gene Expression Master Mix; Invitrogen). Single-cell cDNA was assayed for: *Kiss1, TH, Esr1, Esr2, Pgr, Cacna1g, Cacna1h, Cacna1i, Hcn1 Hcn2 Hcn3 Hcn4; Syn1* was used as housekeeping gene; only Syn1-positive cells were analyzed. Single cells were considered positive for a transcript if their threshold was a minimum of three cycles earlier (eight fold greater) than the false harvests and the reverse transcribed and preamplified water blank sample. TaqMan PrimeTime qPCR assays for mRNAs ([Table 4](#table4){ref-type="table"}) were purchased from IDT.

Tail-tip blood collection for LH pulses {#s4-12}
---------------------------------------

Ovary-intact Kiss1Cre-Cas9 adult female mice with AAV-*lacZ* and AAV-*Esr1* targeted to the arcuate nucleus were singly-housed were handled daily ≥4 wks before sampling. Vaginal cytology was determined for ≥10 days before sampling. As the majority of AAV-*Esr1* arcuate targeted mice (6 of 9) exhibit prolonged cornification typical of estrus, all mice (*Esr1* and *lacZ*) were sampled during estrus. Repetitive tail-tip blood collecting was performed as described ([@bib48]). After the excision of the very tip of the tail, blood (6 µL) was collected every 6 min for 2 hr from 1pm to 3pm. At the end of this frequent sampling period, mice received a single intraperitoneal injection of kisspeptin (65 µg/kg) ([@bib20]). Blood was collected just before and 15 min after kisspeptin injection. GnRH (150 µg/kg) ([@bib17]) was injected 40--45 min after kisspeptin, with blood collected immediately before and 15 min after GnRH injection.

Tail-tip blood collection for LH surge {#s4-13}
--------------------------------------

Ovary-intact Kiss1Cre-Cas9 adult female mice with AAV-*lacZ* and AAV-*Esr1* targeted to the AVPV were singly-housed. Tail blood was collected as above on proestrus at 3, 4 and 5pm EST (lights are off at 5pm EST in the mouse room). One to two weeks later, these same mice were then subjected to OVX + E surgery and tail blood (6 µL) was collected 2--3 days post-surgery at 9am and 5pm EST.

LH assay {#s4-14}
--------

Whole blood was immediately diluted in 54 μL of 0.1M PBS with 0.05% Tween 20% and 0.2% BSA, mixed and kept on ice. Samples were stored at −20°C for a subsequent ultrasensitive LH assay ([@bib48]). Intraassay CV was 2.2%; interassay CVs were 7.3% (low QC, 0.13 ng/mL), 5.0% (medium QC, 0.8 ng/mL) and 6.5% (high QC, 2.3 ng/mL). Functional sensitivity was 0.016 ng/mL.

Ovarian histology {#s4-15}
-----------------

Ovaries were fixed for 24 hr in 10% neutral-buffered formalin, then stored in 70% ethanol until paraffin embedding, sectioning (5 µm) and H and E staining. Every fifth section was examined and *corpra lutea* counted.

Data analysis and statistics {#s4-16}
----------------------------

Data were analyzed offline using custom software written in IgorPro 6.31 (Wavemetrics). For targeted extracellular recordings, mean firing rate in Hz was determined over 5 min of stable recording. In experiments examining I~T~, the peak current amplitude at each step potential (V) was first converted to conductance using the calculated reversal potential of Ca^2+^ (E~Ca~) and G = I/(E~Ca~ - V), because driving force was linear over the range of voltages examined. The voltage dependencies of activation and steady-state inactivation were described with a single Boltzmann distribution: G(V)=G~max~/(1- exp \[(V~1/2~ - V~t~)/k\]), where G~max~ is the maximal conductance, V~1/2~ is the half-maximal voltage, and k is the slope. Current density of I~T~ at each tested membrane potential was determined by dividing peak current by membrane capacitance. LH pulses were detected by a version of Cluster ([@bib51]) transferred to IgorPro using cluster sizes of two points for both peak and nadir and t-scores of two for detection of increases and decreases. Data were analyzed using Prism 7 (GraphPad Software) and reported as mean ± SEM. The number of cells per group is indicated by n and the number of mice by N in [Table 5](#table5){ref-type="table"}. For two-by-two designs, data were normally distributed and analyzed by two-way ANOVA or two-way repeated-measures (RM) with Holm-Sidak post hoc. For two group comparisons, normally-distributed data were analyzed by two-tailed unpaired Student's *t*-test; non-normal data were analyzed by Mann-Whitney U test. For categorical data, for more than three categories, *Chi-*square test of independence was used with Fisher's exact test as post hoc analysis. For two categories, Fisher's exact test was used. For each electrophysiological parameter comparison, no more than three cells per mouse was used in control and KERKO mice; no more than four cells per mouse was used for AAV-infected mice. No less than five mice were tested per parameter. The variance of the data was no smaller within an animal than among animals. For IF staining, LH surge and LH pulse measurements, and reproductive cyclicity, at least three mice were tested per AAV vector.
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###### Number of cells (n) and number of mice (N) in each experiment.

For AAV-injected mice, only animals with bilateral hits are included.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  [Figure 1a, b](#fig1){ref-type="fig"}                                          Control                              KERKO               
  ------------------------------------------------------------------------------ ------------------------------------ ------------------- -------------------
  [Figure 1c--f](#fig1){ref-type="fig"},\                                        Control                              KERKO               
  [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"} left, 1b left                                                                

  Intact n = 11, N = 4                                                           Intact n = 11, N = 5                                     

  OVX n = 11, N = 5                                                              OVX n = 9, N = 4                                         

  OVX + E n = 11, N = 7                                                          OVX + E n = 12, N = 5                                    

  [Figure 2](#fig2){ref-type="fig"}                                              Control                              KERKO               

  n = 8, N = 4                                                                   n = 7, N = 4                                             

  [Figure 3d,e](#fig3){ref-type="fig"}                                           AVPV-AAV-*lacZ*                      AVPV-AAV-*Esr1*g1   AVPV-AAV-*Esr1*g2

  N = 3                                                                          N = 3                                N = 4               

  [Figure 3f](#fig3){ref-type="fig"}                                             AVPV-AAV- *lacZ*                     AVPV-AAV-*Esr1*     

  N = 6                                                                          N = 8 (g1 N = 4, g2 N = 4)                               

  [Figure 3g](#fig3){ref-type="fig"}                                             AVPV-AAV- *lacZ*                     AVPV-AAV-*Esr1*     

  N = 6                                                                          N = 9 (g1 N = 5, g2 N = 4)                               

  [Figure 4d--j](#fig4){ref-type="fig"} and\                                     IF *post hoc*                        PCR *post hoc*      
  [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"} middle, 1b middle                                                            

  *Esr1* n = 15, N = 5                                                           *Esr1* n = 10, N = 4                                     

  *lacZ* n = 14, N = 4                                                           *lacZ* n = 9, N = 3                                      

  uninfected n = 8, N = 4                                                        uninfected n = 4, N = 2                                  

  [Figure 5a--d](#fig5){ref-type="fig"}                                          Arc-AAV-*lacZ*                       Arc-AAV-*Esr1*g1    Arc-AAV-*Esr1*g2

  N = 6                                                                          N = 4                                N = 4               

  [Figure 5e--g](#fig5){ref-type="fig"}                                          Arc-AAV-*lacZ*                       Arc-AAV-*Esr1*      

  N = 6                                                                          N = 8 (g1 N = 4, g2 N = 4)                               

  [Figure 6a--c](#fig6){ref-type="fig"}                                          Arc-AAV-*lacZ*                       Arc-AAV-*Esr1*      

  n = 11, N = 5                                                                  n = 13, N = 5                                            

  [Figure 6d--f](#fig6){ref-type="fig"}                                          Arc-AAV-*lacZ*                       Arc-AAV- *Esr1*     

  n = 10, N = 5                                                                  n = 12, N = 5                                            

  [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"} left, 1b right      KERKO                                AVPV-AAV-*Esr1*     

  n = 12, N = 5                                                                  n = 25, N = 9                                            

  [Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"} left                Control                              KERKO               

  Intact N = 6                                                                   Intact n = 11, N = 7                                     

  OVX N = 6                                                                      OVX n = 11, N = 6                                        

  OVX + E N = 5                                                                  OVX + E n = 9, N = 7                                     

  [Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"} middle              AVPV-AAV-*lacZ*                      AVPV-AAV-*Esr1*     

  N = 7                                                                          N = 9                                                    

  [Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"} middle              Arc-AAV-*lacZ*                       Arc-AAV-*Esr1*      

  N = 5                                                                          N = 5                                                    

  [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}                      AVPV-AAV-*lacZ*                      AVPV-AAV-*Esr1*     

  n = 16, N = 5                                                                  n = 23, N = 5 (g1 N = 3, g2 N = 2)                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Genetic dissection of the different roles of hypothalamic kisspeptin neurons in regulating female reproduction\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Catherine Dulac as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Vincent Prevot (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Wang and colleagues describe results from a series of studies aimed at identifying the physiological roles of estrogen receptors in distinct populations of kisspeptin neurons in the hypothalamus. Using multidisciplinary approaches, the deleted ERα in kisspeptin neurons postnatally. This is an important advance in the field as previous mouse models assessing the functional role of ERα in kisspeptin neurons were neither spatially nor temporally restricted therefore revealing important roles during development (such as in puberty onset) but leaving the role in adult reproductive physiology somewhat unexplored. The findings address a long-standing question, which is central to the field of reproductive neuroendocrinology. Fifteen years after the discovery of the two populations of hypothalamic neurons expressing kisspeptin, which is a neuropeptide playing a key role in puberty onset and fertility, the authors use a conditional and time-controlled Crispr-Cas9 approach in adult mice to demonstrate that estrogen receptor (ER) α expression in the anteroventral periventricular (AVPV) population of kisspeptin neurons is required for the onset of the preovulatory surge and that its expression in the population of kisspeptin neurons in the arcuate nucleus of the hypothalamus (ARH) is required for estrous cyclicity and plays a role in the control of pulsatile LH release. Collectively, the studies are well described and provide novel observations that will be of wide interest. Several technical issues need to be addressed.

Essential revisions:

The microinjection procedures need some further explanation including assessments and definition of \"hits\" and misses. Also, the number of mice in each group is a bit difficult to understand.

Also, the authors should comment a bit more about the predicted \"off target\" effects of the sgRNAs being used.

I am not fully convinced that the deletion of ERα in AVPV kisspeptin neurons in adulthood does not affect estrous cycles. While it is principally more difficult if not impossible to substantiate a negative finding experimentally, in this case it is even more difficult as only a good half of the estrogen-sensitive AVPV kisspeptin neurons are affected by the experimental paradigm presented here (the authors report that 28 ± 1% of AVPV kisspeptin cells expressed ERα post AAV infection while 72 ± 2% of AVPV kisspeptin neurons expressed ERα in the controls; subsection "Design and validation of sgRNAs that target *Esr1*"). Instead of postulating other cells expressing ERα in the control of cycylicity (Discussion, third paragraph), wouldn\'t the intact other half of the estrogen-sensitive AVPV kisspeptin neurons that still express ERα after AAV injection be the simplest explanation for this? This should be discussed.

The images in Figure 3 and in Figure 3---figure supplement 1 and Figure 5---figure supplement 1 are so small that I cannot distinguish any cellular details.

Intriguingly, deletion of the ERα in AVPV Kispeptin neurons blunts the preovulatry surge but does not appear to affect estrous cyclicity. Did the authors check ovarian cytology in their mice to know whether the animals actually ovulate? Do they have any data on the cyclicity of estrogen levels? Did they also check LH pulsatility in these mice?

10.7554/eLife.43999.022

Author response

> Essential revisions:
>
> The microinjection procedures need some further explanation including assessments and definition of \"hits\" and misses. Also, the number of mice in each group is a bit difficult to understand.

Definition of how hits and misses were evaluated are now presented in the Materials and methods, and new Table 5 has been included to clarify the number of cells and mice for each group.

> Also, the authors should comment a bit more about the predicted \"off target\" effects of the sgRNAs being used.

This is a good point and we have included the sites predicted by the Feng Zhang's guide design tool (http://crispr.mit.edu) as possible off-target binding sites are listed in new Table 3. This software is currently not available but is what was used at the start of these studies several years ago. We thus confirmed the sites by software Benchling (https://benchling.com/academic). Benchling predicted fewer sites compared to the previous analysis, but provided no new sites. We included the results from Feng Zhang's guide design tool in the manuscript as these appear to be more rigorous.

> The images in Figure 3 and in Figures 3---figure supplement 1 and Figure 5---figure supplement 1 are so small that I cannot distinguish any cellular details.

The goal of the supplementary figures is to show the general region infected rather than cellular detail, thus these have not been altered. Figure 3D has been enlarged as requested.

> I am not fully convinced that the deletion of ERα in AVPV kisspeptin neurons in adulthood does not affect estrous cycles. While it is principally more difficult if not impossible to substantiate a negative finding experimentally, in this case it is even more difficult as only a good half of the estrogen-sensitive AVPV kisspeptin neurons are affected by the experimental paradigm presented here (the authors report that 28 ± 1% of AVPV kisspeptin cells expressed ERα post AAV infection while 72 ± 2% of AVPV kisspeptin neurons expressed ERα in the controls; subsection "Design and validation of sgRNAs that target Esr1"). Instead of postulating other cells expressing ERα in the control of cycylicity (Discussion, third paragraph), wouldn\'t the intact other half of the estrogen-sensitive AVPV kisspeptin neurons that still express ERα after AAV injection be the simplest explanation for this? This should be discussed.
>
> Intriguingly, deletion of the ERα in AVPV Kispeptin neurons blunts the preovulatry surge but does not appear to affect estrous cyclicity. Did the authors check ovarian cytology in their mice to know whether the animals actually ovulate? Do they have any data on the cyclicity of estrogen levels? Did they also check LH pulsatility in these mice?

The reviewers make a good point with these two comments, which we will address together. The viral CRISPR approach produced a knock down, not a knock out. It is thus possible that the remaining cells with ERα in the AVPV support the continuation of the cycle and we have included this in the Discussion. We think it is the weight of the cycle and surge observations together that need to be considered. LH surge amplitude is clearly attenuated in these mice. This includes both the proestrous surge during the cycle, and the estradiol-induced surge. We included the latter as we shared the reviewer's concern that the cycle may not produce an adequate estradiol level, but this concern is alleviated by providing a sufficient estradiol signal is provided via implantation. Because cycles continue and vaginal cornification depends upon an estradiol rise, we can conclude some cyclic variation of estradiol occurs. In two mice injected with virus in this region, we measured uterine mass on the afternoon of proestrus and it was well within the range that is typically observed in control mice. Uterine mass is linearly related to estradiol levels (Endocrinology 141:396). Vaginal cornification, limited uterine mass data and failure to exhibit a typical LH surge in response to exogenous estradiol together point to a likely sufficient estradiol signal, thus a disruption of the surge-generating mechanism. We cannot, however, rule out a more limited estradiol rise contributing to the blunting of the proestrous surge and have added this to the Discussion. We did not assess LH pulses in these mice. Ovarian cytology in rodents is complicated by the lifespan of the corpra lutea extending several cycles. Ovulation points themselves are difficult to assess histologically. We did, however, examine serial sections through the ovary of these mice as well as some mice with arcuate-targeted viral injections. Mice with *lacZ* targeted to the AVPV had between 10 and 12 corpra lutea (CL) per mouse. There was variability in the *Esr1* mice, with two having similar numbers to controls (11 and 12 CL), two having only four CL each and two not showing any evidence of ovulation. These data have been added to the text of the results and suggest that ovulation is indeed impaired in at least some mice in which estrogen receptor α expression was reduced in AVPV kisspeptin neurons.
